Imunon Inc (IMNN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.89-0.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IMNN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.7% |
| Our one-year growth estimate | diamond | 0.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 29.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
IMNN — capital allocation
Dated 2026-09-29
by reference. The Preferred Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”).
Why it matters: This Phase 3 trial is IMUNON’s main program. Faster enrollment may help it reach its stated goal sooner.
Supportive ifAt the next update, IMUNON says enrollment remains ahead of plan. It keeps its goal to finish enrollment by the first half of 2029.
Worry ifIMUNON says enrollment has fallen behind plan or pushes the completion goal past the first half of 2029.
Why it matters: IMUNON used the financing to support trial enrollment. First-half cash use rose to $7.0 million from $5.8 million a year earlier.
Worry ifA company filing shows cash below $3 million after the financing. Or it reports new debt or stock funding before the next trial update.
Less concerning ifCash stays at or above $3 million. IMUNON reports no new debt or stock funding as it advances OVATION 3.
Why it matters: The trial must stay on track to test whether IMNN-001 helps patients live longer. A pause or safety concern could slow it.
Watch forThe independent Data Monitoring Committee says OVATION 3 can continue. It reports no new safety concerns or trial pause.
Also watch forThe committee calls for a pause, trial changes, or an end to OVATION 3 due to safety concerns.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $550 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,033 loss on $10,000 · 80.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.